SCHEMBL1661803

SCHEMBL1661803

COC(=O)c1ccc2nc(-c3ccc(C4OCCCO4)cc3F)sc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TNF P01375 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 2/20 0.46
MCL1 Q07820 2/20 0.46
NOD1 Q9Y239 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NR2F2 P24468 1/20 0.46
KLF5 Q13887 1/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
ALDH1A1 P00352 3/20 0.46
HSP90AA1 P07900 1/20 0.45
S1PR1 P21453 7/20 0.44
NOD2 Q9HC29 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17801761 0.90 NPC1 (0.48) SMN1; SMN2HPGDMEN1KMT2AGAA
SCHEMBL1661378 0.89 S1PR1 (0.49) SMN1; SMN2LMNAHPGDGAAMAPT
SCHEMBL1661945 0.87 S1PR1 (0.42) SMN1; SMN2LMNAHPGDMEN1KMT2A
SCHEMBL1661351 0.81 S1PR1 (0.61) SMN1; SMN2LMNAHPGDMEN1KMT2A
SCHEMBL1661552 0.81 S1PR1 (0.42) SMN1; SMN2LMNAKDM4ES1PR1S1PR3
SCHEMBL1662511 0.80 APP (0.41) SMN1; SMN2GAAMAPTHTTNPC1
SCHEMBL1662041 0.78 S1PR1 (0.49) SMN1; SMN2LMNAHPGDMEN1KMT2A
SCHEMBL1661668 0.74 S1PR1 (0.37) S1PR1S1PR3
SCHEMBL1661746 0.74 S1PR1 (0.56) S1PR1S1PR3
SCHEMBL1661529 0.73 S1PR1 (0.45) S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306994-B1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC (US) 2013-08-14 EP disclosed
EP-2306994-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF Amgen, Inc (US) 2011-04-13 EP disclosed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 US disclosed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 US disclosed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029611-A1 S1P1 receptor agonists and use thereof S1PR1, S1PR5, S1PR2 SMN1; SMN2 2922/4885LMNA 3214/4885HPGD 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.